Thrombophilic state in young patients with acute myocardial infarction. 2015

Elad Maor, and Paul Fefer, and David Varon, and Nurit Rosenberg, and Nitza Levi, and Hanoch Hod, and Shlomi Matetzky
Leviev Heart Institute, Sheba Medical Center, 52621, Tel Hashomer, Israel, eladmaor@gmail.com.

The prevalence of thrombophilia and dyslipidemia among young survivors of acute coronary syndrome has not been clearly defined. The purpose of the current study was to investigate the prevalence of multiple markers of thrombophilia and dyslipidemia in a cohort of consecutive young survivors of acute coronary syndrome. The study cohort included 156 consecutive young patients (men <45 and women <50 years), admitted to the intensive cardiac care unit with newly diagnosed acute coronary syndrome. Analysis included baseline, clinical and epidemiological characteristics, angiographic coronary anatomy, echocardiographic evaluation, extensive lipid and thrombophilia laboratory profiles, and in-hospital and 1-year clinical outcomes for all patients. Acute myocardial infarction was diagnosed in 142 (92 %) patients, of whom 108 (72 %) had ST-segment elevation. Eighteen (12 %) patients had no traditional risk factors. Low levels of high-density lipoprotein (<40 mg/dL) were found in 101 (65 %) patients, and 49 (34 %) patients had elevated levels of lipoprotein(a) (Lp(a)) (>30 mg/dL). Eighteen (12 %) patients were diagnosed with antiphospholipid antibody syndrome (APS), and 73 (47 %) had at least one laboratory finding consistent with thrombophilia. Patients with APS had significantly higher levels of Lp(a) (46 ± 32 vs. 29 ± 31 mg/dL, p = 0.005). APS is a common prothrombotic state found in young survivors of acute coronary syndrome. Lp(a) levels are elevated among APS patients who present with premature acute coronary syndrome.

UI MeSH Term Description Entries
D008075 Lipoproteins, HDL A class of lipoproteins of small size (4-13 nm) and dense (greater than 1.063 g/ml) particles. HDL lipoproteins, synthesized in the liver without a lipid core, accumulate cholesterol esters from peripheral tissues and transport them to the liver for re-utilization or elimination from the body (the reverse cholesterol transport). Their major protein component is APOLIPOPROTEIN A-I. HDL also shuttle APOLIPOPROTEINS C and APOLIPOPROTEINS E to and from triglyceride-rich lipoproteins during their catabolism. HDL plasma level has been inversely correlated with the risk of cardiovascular diseases. High Density Lipoprotein,High-Density Lipoprotein,High-Density Lipoproteins,alpha-Lipoprotein,alpha-Lipoproteins,Heavy Lipoproteins,alpha-1 Lipoprotein,Density Lipoprotein, High,HDL Lipoproteins,High Density Lipoproteins,Lipoprotein, High Density,Lipoprotein, High-Density,Lipoproteins, Heavy,Lipoproteins, High-Density,alpha Lipoprotein,alpha Lipoproteins
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009203 Myocardial Infarction NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION). Cardiovascular Stroke,Heart Attack,Myocardial Infarct,Cardiovascular Strokes,Heart Attacks,Infarct, Myocardial,Infarction, Myocardial,Infarctions, Myocardial,Infarcts, Myocardial,Myocardial Infarctions,Myocardial Infarcts,Stroke, Cardiovascular,Strokes, Cardiovascular
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D016736 Antiphospholipid Syndrome The presence of antibodies directed against phospholipids (ANTIBODIES, ANTIPHOSPHOLIPID). The condition is associated with a variety of diseases, notably systemic lupus erythematosus and other connective tissue diseases, thrombopenia, and arterial or venous thromboses. In pregnancy it can cause abortion. Of the phospholipids, the cardiolipins show markedly elevated levels of anticardiolipin antibodies (ANTIBODIES, ANTICARDIOLIPIN). Present also are high levels of lupus anticoagulant (LUPUS COAGULATION INHIBITOR). Anti-Phospholipid Antibody Syndrome,Anti-Phospholipid Syndrome,Antiphospholipid Antibody Syndrome,Hughes Syndrome,Anti Phospholipid Antibody Syndrome,Anti Phospholipid Syndrome,Antibody Syndrome, Anti-Phospholipid,Antibody Syndrome, Antiphospholipid,Antiphospholipid Antibody Syndromes,Syndrome, Anti-Phospholipid,Syndrome, Anti-Phospholipid Antibody,Syndrome, Antiphospholipid,Syndrome, Antiphospholipid Antibody,Syndrome, Hughes

Related Publications

Elad Maor, and Paul Fefer, and David Varon, and Nurit Rosenberg, and Nitza Levi, and Hanoch Hod, and Shlomi Matetzky
January 2021, Kardiologia polska,
Elad Maor, and Paul Fefer, and David Varon, and Nurit Rosenberg, and Nitza Levi, and Hanoch Hod, and Shlomi Matetzky
January 2008, Saudi medical journal,
Elad Maor, and Paul Fefer, and David Varon, and Nurit Rosenberg, and Nitza Levi, and Hanoch Hod, and Shlomi Matetzky
January 2008, Clinical hemorheology and microcirculation,
Elad Maor, and Paul Fefer, and David Varon, and Nurit Rosenberg, and Nitza Levi, and Hanoch Hod, and Shlomi Matetzky
March 2013, Diabetic medicine : a journal of the British Diabetic Association,
Elad Maor, and Paul Fefer, and David Varon, and Nurit Rosenberg, and Nitza Levi, and Hanoch Hod, and Shlomi Matetzky
July 2012, Clinical and experimental pharmacology & physiology,
Elad Maor, and Paul Fefer, and David Varon, and Nurit Rosenberg, and Nitza Levi, and Hanoch Hod, and Shlomi Matetzky
November 1995, Cardiologia (Rome, Italy),
Elad Maor, and Paul Fefer, and David Varon, and Nurit Rosenberg, and Nitza Levi, and Hanoch Hod, and Shlomi Matetzky
April 2014, Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences,
Elad Maor, and Paul Fefer, and David Varon, and Nurit Rosenberg, and Nitza Levi, and Hanoch Hod, and Shlomi Matetzky
January 2013, American journal of cardiovascular disease,
Elad Maor, and Paul Fefer, and David Varon, and Nurit Rosenberg, and Nitza Levi, and Hanoch Hod, and Shlomi Matetzky
June 1996, Journal of the Royal Society of Health,
Elad Maor, and Paul Fefer, and David Varon, and Nurit Rosenberg, and Nitza Levi, and Hanoch Hod, and Shlomi Matetzky
January 2011, Heart and vessels,
Copied contents to your clipboard!